Denali Therapeutics Inc. DNLI Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$512.54M-21.2% | -$422.77M-191% | -$145.22M+55.5% | -$325.99M-12.2% | ||
| $11.18M+43.5% | $7.8M-53.4% | $16.73M+61.1% | $10.38M+20.8% | ||
| $99.63M-3.2% | $102.88M-4.8% | $108.1M+8.3% | $99.85M+17.1% | ||
| -$412.6M-18.7% | -$347.69M+2.9% | -$357.99M-46.3% | -$244.72M-15.8% | ||
| —— | $15.91M+23.0% | $12.94M-27.4% | $17.83M+110% | ||
| $255.28M— | —— | $249.31M— | —— | ||
| $189.22M— | —— | $17.82M-94.3% | $310.67M+1,506% | ||
| $31.9M— | —— | —— | —— | ||
| -$422.1M-16.1% | -$363.61M+2.0% | -$370.93M-41.3% | -$262.55M-19.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Denali Therapeutics Inc.'s cash flow data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.